Drug Profile
VGX 3100
Alternative Names: Human papillomavirus vaccine-VGX Pharmaceuticals; pGX 3001; pGX-3002; VGX-3100Latest Information Update: 03 Oct 2023
Price :
$50
*
At a glance
- Originator University of Pennsylvania
- Developer Inovio Pharmaceuticals
- Class Antineoplastics; Cancer vaccines; DNA vaccines; Immunotherapies; Papillomavirus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Cervical intraepithelial neoplasia
- Phase II Anal intraepithelial neoplasia; Human papillomavirus infections; Vulvar intraepithelial neoplasia
Most Recent Events
- 09 Aug 2023 Discontinued - Phase-III for Cervical intraepithelial neoplasia in USA (IM)
- 01 Mar 2023 Efficacy results from the phase III REVEAL 2 clinical trial in Cervical intraepithelial neoplasia released by Inovio Pharmaceuticals
- 14 Sep 2022 Inovio Pharmaceuticals completes the phase III REVEAL 2 trial in Cervical intraepithelial neoplasia USA, Argentina, Belgium, Brazil, Estonia, Finland, Italy, Lithuania, Poland, Puerto Rico, South Africa, Spain, the UK, in September 2022 (IM) (NCT03721978) (EudraCT2018-004114-17)